|
|
Volumn 11, Issue , 2012, Pages 6-8
|
|
2011 in reflection
[No Author Info available]
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ALEMTUZUMAB;
ALIPOGENE TIPARVOVEC;
ASUNAPREVIR;
ATORVASTATIN;
BELIMUMAB;
BEVACIZUMAB;
BOCEPREVIR;
BRENTUXIMAB VEDOTIN;
BRIAKINUMAB;
CEDIRANIB;
DALCETRAPIB;
DANOPREVIR;
FINGOLIMOD;
FUMARIC ACID DIMETHYL ESTER;
INIPARIB;
INSULIN DERIVATIVE;
IPILIMUMAB;
IVACAFTOR;
NECITUMUMAB;
ORAL ANTIDIABETIC AGENT;
PSI 7977;
RIBAVIRIN;
SILDENAFIL;
TELAPREVIR;
TELCAGEPANT;
TORCETRAPIB;
TRANSFORMING GROWTH FACTOR BETA ANTIBODY;
UNCLASSIFIED DRUG;
UNINDEXED DRUG;
VEMURAFENIB;
VORAPAXAR;
ZIBOTENTAN;
ACUTE CORONARY SYNDROME;
BIOTECHNOLOGY;
BREAST CANCER;
CASTRATION RESISTANT PROSTATE CANCER;
DRUG APPROVAL;
DRUG CONTROL;
DRUG EFFICACY;
DRUG INDUSTRY;
DRUG RESEARCH;
DRUG SAFETY;
HUMAN;
LUNG NON SMALL CELL CANCER;
MIGRAINE;
MULTIPLE SCLEROSIS;
PRIORITY JOURNAL;
PSORIASIS;
PUBLIC-PRIVATE PARTNERSHIP;
SHORT SURVEY;
TRANSLATIONAL RESEARCH;
TRIPLE NEGATIVE BREAST CANCER;
|
|
EID: 84855374173
PISSN: 14741776
EISSN: 14741784
Source Type: Journal
DOI: 10.1038/nrd3643 Document Type: Erratum |
|
Times cited : (10)
|
|
References (0)
|